Life sciences investor Casdin Capital significantly increased its position in Scholar Rock (SRRK), boosting its holdings by 90% to 665,000 shares. According to a quarterly disclosure that reflects holdings as of June 30, 2026, the firm's stake grew to a reported value of $36.58 million. These mandatory 13F filings are released with a delay, so this trade occurred sometime between March 31 and June 30.
The increased investment came as Scholar Rock headed towards a significant catalyst. The clinical-stage biopharmaceutical company is awaiting an FDA decision on its lead drug candidate, apitegromab, for spinal muscular atrophy, with a target date of September 30, 2026. [2, 4, 5, 12] For the quarter ending June 30, Scholar Rock reported a strong cash position of $492.1 million as it prepares for a potential U.S. commercial launch. [2, 5]